A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...

Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...

The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

Companies in the defense tech, healthcare, robotics and dairy sectors will invest over $240 million in Detroit, Wixom and ...

An analysis of The New Consumer and Coefficient Capital's latest research revealing where venture capitalists should place ...

Researchers studied synthetic lethality pathway using Promega NanoBRET(R) TE technology -- Study is the first to characterize uncompetitive binding directly in live cells, illuminating a mechanistic ...

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen ...

It's love at first bite with these romantic Valentine's Day dinners. Elegant scallops, flavorful steaks and impressive pasta ...

A Stanford Medicine study found that human aging speeds up at 44 and 60. Here, doctors share how to quell it by cutting alcohol, strength training, and more.

The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which the companies ...

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer: Cambridge, UK Wednesday, ...